RxDoctor Payments Data

Nekenzie Jones, NP

Family · Saint George, UTNPI 1649936535

Payments from drug & device makers

$6,962in general payments, 2019–2025

Across 321 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Sanofi$454
  • Madrigal Pharmaceuticals$332
  • Regeneron Healthcare Solutions, Inc.$324
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,78898%
  • Education$1742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,962 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$104,324
Medicare patients
425
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase35$484,352
StelaraUstekinumab17$457,596
CreonLipase/Protease/Amylase43$151,287
LinzessLinaclotide26$22,587
Mesalamine45$20,536
Budesonide DrBudesonide25$6,752
Omeprazole270$5,266
Cholestyramine LightCholestyramine35$5,090
MovantikNaloxegol Oxalate11$4,685
Lubiprostone19$4,025
Famotidine266$3,987
Pantoprazole Sodium224$3,768
PrevaliteCholestyramine18$3,490
Colestipol Hcl32$3,344
Dicyclomine Hcl90$3,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$156$484,35235 claims
Johnson & JohnsonStelara$1,033$457,59617 claims
AbbVieCreon, Linzess$1,590$173,87469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.

Other family in Saint George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →